2019
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology 2019, 76: 1219-1229. PMID: 31329216, PMCID: PMC6646979, DOI: 10.1001/jamaneurol.2019.2050.Peer-Reviewed Original ResearchAZD0530 treatmentAdverse eventsPrimary outcomeTreatment groupsAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseasePositron emission tomography evidenceMini-Mental State Examination scoreAlzheimer's Disease Assessment Scale-cognitive subscaleCerebral metabolic declineFrequent adverse eventsSecondary end pointsCerebral metabolic rateMild Alzheimer's dementiaState Examination scorePlasma drug levelsClinical Dementia RatingVolumetric magnetic resonanceEffect of AZD0530Neuronal cell surfaceModified intentionTreat populationSecondary outcomesNeuropsychiatric InventoryEfficacy analysis
2015
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's Research & Therapy 2015, 7: 35. PMID: 25874001, PMCID: PMC4396171, DOI: 10.1186/s13195-015-0119-0.Peer-Reviewed Original ResearchRegional cerebral glucose metabolismCerebral glucose metabolismTreatment of patientsClinical efficacy measuresModerate Alzheimer's diseaseAlzheimer's diseaseEfficacy measuresGlucose metabolismCentral nervous system availabilityMultiple ascending dose studyFluorodeoxyglucose positron emission tomographyPhase IIa clinical trialMini-Mental State Examination scoreCentral nervous system penetrationPromising new therapeutic targetCSF drug levelsMultiple ascending doseOligomeric amyloid betaPhase Ib trialPlacebo-controlled trialAscending dose studyCongestive heart failureCerebrospinal fluid penetrationDisease-modifying therapiesIIa clinical trial